MX350336B - Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberacion del principio activo, util para aumentar la reserva ovarica en mujeres y para aliviar sintomas asociados a la menopausia. - Google Patents

Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberacion del principio activo, util para aumentar la reserva ovarica en mujeres y para aliviar sintomas asociados a la menopausia.

Info

Publication number
MX350336B
MX350336B MX2014007957A MX2014007957A MX350336B MX 350336 B MX350336 B MX 350336B MX 2014007957 A MX2014007957 A MX 2014007957A MX 2014007957 A MX2014007957 A MX 2014007957A MX 350336 B MX350336 B MX 350336B
Authority
MX
Mexico
Prior art keywords
dhea
active principle
release
women
modulating
Prior art date
Application number
MX2014007957A
Other languages
English (en)
Other versions
MX2014007957A (es
Inventor
Chen Shu-Chen
Ariel Fuentes García Frans
Del Carmen Beltrán Apablaza Marianela
Original Assignee
Univ Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chile filed Critical Univ Chile
Publication of MX2014007957A publication Critical patent/MX2014007957A/es
Publication of MX350336B publication Critical patent/MX350336B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

La presente invención se refiere a un anillo vaginal de liberación sostenida, caracterizado porque comprende de 1% a 32% en peso, en relación al peso total de la formulación, de dehidroepiandrosterona como agente activo, y de 2% a 25% en peso, en relación al total de la formulación, de polivinilpirrolidona K-30 como modulador de la liberación del agente activo.
MX2014007957A 2011-12-29 2011-12-29 Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberacion del principio activo, util para aumentar la reserva ovarica en mujeres y para aliviar sintomas asociados a la menopausia. MX350336B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/056023 WO2013098592A1 (es) 2011-12-29 2011-12-29 Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia

Publications (2)

Publication Number Publication Date
MX2014007957A MX2014007957A (es) 2015-11-06
MX350336B true MX350336B (es) 2017-09-04

Family

ID=48696405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007957A MX350336B (es) 2011-12-29 2011-12-29 Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberacion del principio activo, util para aumentar la reserva ovarica en mujeres y para aliviar sintomas asociados a la menopausia.

Country Status (12)

Country Link
US (1) US9066956B2 (es)
EP (1) EP2799042A4 (es)
JP (1) JP5887424B2 (es)
KR (1) KR101622861B1 (es)
CN (1) CN104271084B (es)
BR (1) BR112014014308A2 (es)
CA (1) CA2860133C (es)
CR (1) CR20140270A (es)
EA (1) EA027633B1 (es)
MX (1) MX350336B (es)
NI (1) NI201400067A (es)
WO (1) WO2013098592A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3272333A1 (en) 2016-07-22 2018-01-24 Chemo Research, S.L. Vaginal composition comprising a combination of estrogen and vitamin d
CN108537785B (zh) * 2018-04-04 2021-04-30 北京大学人民医院 一种子宫超声微蠕动视频处理方法
US10918649B2 (en) * 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
AU2020397648B2 (en) 2019-12-06 2022-03-24 Prathima Chowdary Sustained release estrogen vaginal ring pessary for treatment of atrophy, cystitis and uterovaginal prolapse

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1100541C (zh) 1993-01-19 2003-02-05 恩多研究公司 脱氢表雄酮的治疗用途和传送系统
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
ES2098193B1 (es) 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
WO1999021562A1 (en) 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
NZ528377A (en) * 2001-03-27 2005-05-27 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
EP1350541A1 (de) 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Verwendung von einem Dehydroepiandrosteron und einem Estradiol Derivat zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung klimakterischer Beschwerden in der Postmenopause
US20060089308A1 (en) 2004-10-26 2006-04-27 American Infertility Of New York Method of improving ovulation induction using an androgen such as dehydroepiandrosterone
US9375436B2 (en) 2004-10-26 2016-06-28 Norbert Gleicher Androgen treatment in females
US8067400B2 (en) 2004-10-26 2011-11-29 American Infertility Of New York Androgen treatment in females
US8501719B2 (en) 2005-11-08 2013-08-06 American Infertility Of New York Androgen treatment in females
US8501718B2 (en) 2005-11-08 2013-08-06 American Infertility Of New York Androgen treatment in females
US7615544B2 (en) 2004-10-26 2009-11-10 American Infertility Of New York Method of improving cumulative embryo score and quantity of fertilized oocytes, increasing euploidy rate and of normalizing ovarian function using an androgen such as dehydroepiandrosterone
WO2007070067A1 (en) * 2005-12-16 2007-06-21 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
CN105581976A (zh) * 2007-06-26 2016-05-18 沃纳奇尔科特有限责任公司 用于递送大分子和水溶性药物的阴道内药物递送装置
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
US9066956B2 (en) 2015-06-30
BR112014014308A2 (pt) 2017-06-13
JP2015506933A (ja) 2015-03-05
CR20140270A (es) 2014-10-31
CA2860133C (en) 2016-10-11
US20150004214A1 (en) 2015-01-01
KR101622861B1 (ko) 2016-05-19
JP5887424B2 (ja) 2016-03-16
EP2799042A4 (en) 2015-02-11
MX2014007957A (es) 2015-11-06
CA2860133A1 (en) 2013-07-04
EA201491165A1 (ru) 2014-12-30
WO2013098592A1 (es) 2013-07-04
EA027633B1 (ru) 2017-08-31
CN104271084B (zh) 2017-03-01
NI201400067A (es) 2016-02-15
EP2799042A1 (en) 2014-11-05
KR20140109987A (ko) 2014-09-16
CN104271084A (zh) 2015-01-07

Similar Documents

Publication Publication Date Title
MX2014007957A (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberacion del principio activo, util para aumentar la reserva ovarica en mujeres y para aliviar sintomas asociados a la menopausia.
WO2013022783A3 (en) Progesterone containing oral dosage forms and related methods
PE20130524A1 (es) Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis
JP2013542246A5 (es)
HRP20192026T4 (hr) Formulacija tableta od neratinib maleata
HRP20240121T1 (hr) Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
RU2007132852A (ru) Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение
JP2018527305A5 (es)
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
JP2013516493A5 (es)
MX2013012038A (es) Combinacion de carotenoide, fitoestrogeno y vitamina c para la humectacion de la piel.
AR088704A1 (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberacion del principio activo, util para aumentar la reserva ovarica en mujeres y para aliviar sintomas asociados a la menopausia
CO7151514A2 (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia.
MX2014007523A (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberacion del principio activo, util como anticonceptivo de uso continuo en mujeres.
DOP2014000143A (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia
ECSP14008170A (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia
GT201400124A (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia
WO2011094208A3 (en) Methods and pharmaceutical compositions for preventing and treating renal impairment
UA68331U (ru) Способ синхронизации половых циклов у кобыл
BR112014005626A2 (pt) combinações compreendendo um modulador do receptor de s1p
WO2012154725A3 (en) Steroid-sparing effects of beta-adrenergic inverse agonists and use thereof
UA64808U (ru) Способ фармакокорекции синдрома эндогенной интоксикации, возникающего в постдекомпрессионном периоде краш-синдрома
UA114517C2 (uk) Спосіб лікування порушення жіночого сексуального збудження, порушення жіночого сексуального потягу, порушення жіночого оргазму й порушення жіночого сексуального інтересу
CL2007002765A1 (es) Formulacion farmaceutica que comprende un complejo de hidroxipropil-beta-ciclodextrina-progesterona, carboximetilquitosano, celulosa microcristalina y opcionalmente estearato de magnesio; procedimiento de preparacion; y uso para tratar desordenes ginecologicos.

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: UNIVERSIDAD DE CHILE

FG Grant or registration